DOI: 10.5061/dryad.q2bvq83gk
title: F2R polymorphisms and clopidogrel efficacy and safety in patients with minor stroke or TIA: supplemental figures and tables

description: Objective: To investigate the association between protease-activated
 receptors-1 (PAR-1) gene F2R polymorphisms and efficacy of clopidogrel for
 minor stroke or transient ischemic attack (TIA). Methods: Three
 single-nucleotide polymorphisms (CYP2C19*2 [681G&gt;A, rs4244285],
 CYP2C19*3 [636G&gt;A, rs4986893] and F2R [IVSn-14 A/T, rs168753] were
 genotyped among 2,924 patients randomized to clopidogrel plus aspirin
 (n=1461) or aspirin alone (n=1463). The primary efficacy outcome was new
 stroke (ischemic or hemorrhagic) and the safety outcome was any bleeding.
 Results: Overall, 859(29.4%) were AA homozygotes, 1479(50.6%)
 were AT heterozygotes and 586(20.0%) were TT homozygotes for F2R IVSn -14
 polymorphisms; 1716 (58.7%) were carriers of at least one CYP2C19
 loss-of-function allele (*2 or *3). Compared with aspirin alone, patients
 with clopidogrel-aspirin treatment had a low risk of new stroke in
 patients with AT genotype (7.6% vs. 11.3%; hazard ratio [HR], 0.63; 95%
 confidence interval [CI], 0.44-0.89) and TT genotype (5.8% vs. 11.6%; HR,
 0.46; 95% CI, 0.25-0.82) but not in carriers of the AA genotype (10.8% vs.
 11.6%; HR, 0.95; 95% CI, 0.63-1.44) (p=0.03 for interaction). The
 association between F2R IVSn -14 A/T polymorphism and clopidogrel response
 was present regardless of the carrier status of the CYP2C19
 loss-of-function alleles. The F2R IVSn -14 genotypes were not associated
 with the risk of any bleeding for clopidogrel-aspirin treatment (P=0.66
 for interaction). Conclusions: Among patients with minor ischemic stroke
 or TIA who were receiving clopidogrel and aspirin, those carrying F2R IVSn
 -14 T allele had a lower rate of recurrent stroke than those who were not.
 Clinicaltrials.gov Identifier: NCT00979589.
description: Supplemental Data corresponding to research paper
 '<em>F2R</em> Polymorphisms and Clopidogrel Efficacy and
 Safety in Patients with Minor Stroke or TIA' It
 contains supplemental figures and supplemental tables for this
 paper.
description: Figure e-1. PAR-1
 pathway and clopidogrel action Figure e-2. Flow diagram of
 participants in the genetic substudy for F2R IVSn -14 A/T
 Table e-1. Baseline
 differences between individuals with and without genetic data
 Table e-2. Event rate and
 effect of clopidogrel-aspirin <i>vs</i>. aspirin in patients
 with genotype data and in the parent trial. Table e-3. Baseline
 characteristics between treatment groups for each genotype of the
 <i>F2R</i> IVSn -14 A/T polymorphism. Table e-4. Baseline
 characteristics among groups stratified by <i>CYP2C19</i>
 Loss-of-function allele carrier status and <i>F2R</i> IVSn -14
 A/T genotype Table e-5. Baseline
 characteristics between treatment groups stratified by
 <i>CYP2C19</i> Loss-of-function allele carrier status and
 <i>F2R</i> IVSn -14 A/T genotype. Table e-6.
 Effect of clopidogrel-aspirin as compared with aspirin on clinical outcome
 stratified by <i>CYP2C19</i> loss-of-function allele carrier
 status. Table
 e-7. Rate of bleeding and effect of clopidogrel-aspirin
 <i>vs</i>. aspirin in carriers of both
 <i>CYP2C19</i> Loss-of-function alleles and at least one T
 allele of <i>F2R</i> IVSn -14 A/T